One overarching objective of our studies is to ascertain potential combinations of APE1 inhibition with clinically approved drugs that impinge on pathways impacted by altered APE1 expression, initially in pancreatic cancer, but eventually in other cancers. The gene discussed is APEX1; the disease is familial pancreatic carcinoma.